HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Oncternal Therapeutics (NASDAQ:ONCT) but lowers the price target from $28 to $19.
May 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncternal Therapeutics' price target was reduced from $28 to $19 by HC Wainwright & Co., although the Buy rating was maintained.
While the reduction in price target could suggest a tempered outlook on the stock's future performance, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the news.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100